Home
Search results “Leuprolide for prostate cancer”
Hormone Therapy Side Effects
 
01:48
Edward Weber, M.D. Medical Oncologist, describes the side effects of cardiac complications when receiving Androgen Deprivation Therapy, ADT, also known as Hormone Therapy, for treatment of Prostate Cancer. ADT is used to reduce the production of testosterone needed for the growth of prostate cancer cells. But ADT can have cardiac complications, especially on men with a history of heart disease. Video Development: Dean Dubinsky Video Transcript: Prostate Cancer Free Foundation. Increasing Knowledge - Building Hope. Edward Weber, M.D. Medical Oncologist, Prostate Cancer Results Study Group. Men with prostate cancer are much more likely to die of cardiac disease and not from prostate cancer, unless the diagnosis is made at a very late stage.  For that reason, a man’s cardiac history, his cardiovascular risk factors, and the choice of which drug to use for ADT are very critical issues. Androgen deprivation therapy, ADT, the  mainstay of treatment for years, is associated with a 10-20% increased risk of cardiac complications, such as a heart attack, stroke, or sudden death. If a man has already had two important cardiac events before starting ADT the risk of another cardiac event is greatly increased. Surprisingly these serious problems can occur within the  first 6 - 12 months. Degarelix (Firmagon), the newer drug for ADT, is less toxic to the heart than leuprolide (Lupron), and, for many clinicians, is becoming the preferred agent for hormone therapy. Every man before starting ADT needs to have a thorough evaluation for cardiac risk factors. This exam should focus on past history of cardiovascular disease, hypertension, diabetes, elevated cholesterol and triglycerides, and the life-style factors diet and exercise habits.   In some men this pre-ADT evaluation will lead to choosing Firmagon over Lupron, or receiving the shortest period of drug exposure as possible, or beginning a program for modification of cardiac risk factors — or possibly avoiding the use of these drugs entirely. Prostate Cancer Free Foundation https://prostatecancerfree.org
Prostate Cancer Hormone Side Effects
 
01:49
Edward Weber, M.D. Medical Oncologist, describes the side effects of cardiac complications when receiving Androgen Deprivation Therapy, ADT, also known as Hormone Therapy, for treatment of Prostate Cancer. Video Developer: Dean Dubinsky Website: ProstateCancerFree.org Transcript: Prostate Cancer Free Foundation. Increasing Knowledge – Building Hope. Edward Weber, M.D. Medical Oncologist, Prostate Cancer Results Study Group. Men with prostate cancer are much more likely to die of cardiac disease and not from prostate cancer, unless the diagnosis is made at a very late stage. For that reason, a man’s cardiac history, his cardiovascular risk factors, and the choice of which drug to use for ADT are very critical issues. Androgen deprivation therapy, ADT, the mainstay of treatment for years, is associated with a 10-20% increased risk of cardiac complications, such as a heart attack, stroke, or sudden death. If a man has already had two important cardiac events before starting ADT the risk of another cardiac event is greatly increased. Surprisingly these serious problems can occur within the first 6 – 12 months. Degarelix (Firmagon), the newer drug for ADT, is less toxic to the heart than leuprolide (Lupron), and, for many clinicians, is becoming the preferred agent for hormone therapy. Every man before starting ADT needs to have a thorough evaluation for cardiac risk factors. This exam should focus on past history of cardiovascular disease, hypertension, diabetes, elevated cholesterol and triglycerides, and the life-style factors diet and exercise habits. In some men this pre-ADT evaluation will lead to choosing Firmagon over Lupron, or receiving the shortest period of drug exposure as possible, or beginning a program for modification of cardiac risk factors — or possibly avoiding the use of these drugs entirely. Prostate Cancer Free Foundation. www.prostatecancerfree.org
Possible Side Effects of Prostate Cancer Treatment
 
04:39
Treatment options for prostate cancer can lead to a range of side effects. Dr. Arthur Burnett, Patrick C. Walsh Distinguished Professor of Urology, Director, Basic Science Laboratory in Neurourology and Director, Male Consultation Clinic at Johns Hopkins Medical Institutions discusses these possible side effects and how men and their family and caregivers can manage the impact of treatment.
Views: 4183 Genomic Health, Inc.
Prostate Cancer Injections
 
02:05
Newly-approved prostate cancer ejections giving cancer patients more quality of life.
Dr. Slovin on an Ongoing Study With Degarelix Leuprolide in Prostate Cancer
 
00:55
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Views: 71 OncLiveTV
Dr. Andre Goy on Neoadjuvant Leuprolide and Abiraterone in High Risk Localized Prostate Cancer
 
01:35
Andre Goy, MD, MS, chief, Lymphoma Division, chairman, John Theurer Cancer Center at Hackensack University Medical Center, discusses a phase II trial that combined leuprolide acetate with abiraterone acetate before prostatectomy in patients with localized high-risk prostate cancer. Read more at http://www.onclive.com/onclive-tv/Dr-Goy-on-Neoadjuvant-Hormonal-Therapy-Plus-Zytiga
Views: 430 OncLiveTV
Neoadjuvant abiraterone acetate plus leuprolide acetate for localised high-risk prostate cancer
 
05:04
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study that evaluated the clinical and biological heterogeneity of response and resistance to neoadjuvant abiraterone acetate, a prodrug of abiraterone, a CYP17 inhibitor that lowers serum testosterone, plus leuprolide acetate, a luteinizing hormone-releasing hormone agonist (LHRHa), versus LHRHa for patients with localised high-risk prostate cancer.
Firmagon V Lupron + PCa Remissions
 
04:45
Purchase a transcript here: https://rivanna-health-publications.myshopify.com
Views: 1143 ProstateForum
Leuprolide Test
 
16:02
See the Seitz vlog, Season 2, Episode 72 Dan starts the vlog off while boiling some chicken breasts for Hudsyn's diet. Then he and the kids head off to Children's Mercy Clinics for Hudsyn's Leuprolide test which is to check hormone levels so they can get a better understanding about her early onset puberty. - - - - - - - - - - - - - - - - - -Music by - CLOUDS Clouds by Joakim Karud http://soundcloud.com/joakimkarud Music promoted by Audio Library https://youtu.be/YrvBTBmqVPE Just Cool Music promoted by Audio Library https://youtu.be/-7YDBIGCXsYJust Cool by WowaMusik https://soundcloud.com/wowamusik Creative Commons — Attribution 3.0 Unported— CC BY 3.0 http://creativecommons.org/licenses/b... Music promoted by Audio Library https://youtu.be/QuIoQ04e4zA Stories by A Himitsu https://soundcloud.com/a-himitsu Creative Commons — Attribution 3.0 Unported— CC BY 3.0 http://creativecommons.org/licenses/b... Music promoted by Audio Library https://youtu.be/oA9txZtAUaI - - - - - - - - - - - - - - - I film our vlogs almost exclusively with my iPhone 7 plus. I occasionally supplement with a GoPro Session 4, a DJI Phantom 2, and a DJI Spark. Thanks for watching our vlogs! https://seetheseitzfam.com/ https://www.facebook.com/SeeTheSeitz https://twitter.com/danseitz https://www.facebook.com/HopeForHudsyn (The first 100+ episodes of this vlog were filmed and edited exclusively with and on an iPhone)
Views: 3958 Dan Seitz
Androgen deprivation therapy for prostate cancer
 
01:19
Today, CancerBro will explain what is prostate cancer deprivation therapy. Video Transcript: The next treatment modality is androgen deprivation therapy. For this, we first have to understand the hormonal axis causing the testosterone release. Pituary gland releases LH and FSH, which directly acts on the testis to release testosterone. ACTH released from pituitary gland acts on the adrenal gland to release DHEA, which subsequently gets converted into testosterone. The testosterone released from testis and adrenal gland enters the prostate cell and gets converted into DHT which causes the growth and survival of prostate cancer cells. We can block this pathway, to reduce the action of testosterone on prostate cancer cells. GNRH agonists or antagonists prevents the release of LH, FSH and ACTH from pituitary gland. Then come the cytochrome 17P inhibitors that prevent the release of testosterone from testis and adrenal gland. And finally there are androgen receptor blockers that prevents the binding of testosterone to prostate cancer cells, thereby preventing it's action. Another method for androgen deprivation is surgical castration in which both testes are removed. Unlike medical constration it is a one time procedure. CancerBro is also active on most social media channels. Follow him to get rich and authoritative content related to cancer awareness, risk factors, symptoms, diagnosis, treatment, etc. Facebook - https://www.facebook.com/officialcancerbro/ Instagram - https://www.instagram.com/official_cancerbro/ Twitter - https://twitter.com/cancer_bro/ Website - http://www.cancerbro.com/
Views: 69 CancerBro
Can Advanced Prostate Cancer Be Cured?
 
41:10
http://www.balancedhealthtoday.com http://www.balancedhealthtoday.com/endosterol.html Currently, no cure exists for advanced prostate cancer. Men can benefit, however, in several ways. Some treatments slow the growth of the cancer. Others reduce symptoms caused by the disease. Until recently, no therapy was offered to prolong life. However, the recently approved chemotherapy drug Taxotere, when taken with the steroid prednisone, has been proven to extend survival by several months. Taxotere is approved only for men with cancer that no longer responds to hormone therapy (called hormone refractory prostate cancer). In addition, Provenge, a "vaccine" for the treatment of advanced prostate cancer, does appear to extend survival -- by months for most patients, by years for some. Provenge isn't your everyday vaccine. It's an immune therapy created by harvesting immune cells from a patient, genetically engineering them to fight prostate cancer, and then infusing them back into the patient. It's approved only for treatment of patients with few or no symptoms who have prostate cancer that has spread outside the prostate and no longer responds to hormone therapy. http://www.balancedhealthtoday.com/store http://www.balancedhealthtoday.com/store/endosterol.html
Views: 165 Martina Santiago
How To Prepare Leuprolide Acetate Injection?
 
02:09
Many of doctors or nurses do not know how to prepare Leuprolide acetate injection, so we have filmed this video tutorial so that you can understand it better. The procedure seems to be quite complicated, but it is very simple. But you must take during attaching needle, otherwise material may ooze out due to negative pressure.
Views: 40258 Dr. Vikram
Side effects of Lupron
 
09:58
Views: 8437 Karina Diaz
Lupron side effects
 
09:28
6 days after first Lupron injection. Side effects and vitamins I am currently taking.
Views: 12091 Alexandria Marchak
Leuprolide Acetate Injection (Lupron)
 
01:14
Leuprolide Acetate (Lupron) is related to a naturally occurring hormone called gonadotropin releasing hormone (GnRH). Leuprolide Acetate has also been used to treat endometriosis, uterine fibroids, early puberty, and as part of the process to stimulate multiple eggs for assisted reproductive technologies. The strength of Leuprolide Acetate is 1mg/0.2ml. Leuprolide Acetate is administered as a subcutaneous injection using insulin syringes. Insulin syringes are used because the measurement on the syringe is in units (i.e.: 10 units is equivalent to 0.1ml/cc). For the role it plays in assisted reproductive technologies, Leuprolide Acetate is used to reduce the amount of estrogen and testosterone in the body. This decrease in estrogen production will prevent ovulation and stop menstrual periods. For questions regarding medication administration or to speak to our nurse or pharmacist, please call 877-334-1610.
Views: 72629 Village Pharmacy
Dr. Concepcion on The Use of Eligard in Prostate Cancer Treatment
 
02:28
Raoul Concepcion, MD, director, Comprehensive Prostate Center, discusses the use of Eligard in the treatment of prostate cancer with OncLive during the LUGPA Annual Meeting.
Views: 738 OncLiveTV
Early Castration Resistance depends on Lupron Regimen .mp4
 
05:33
Early Castration Resistance depends on Lupron Regimen .mp4
Views: 712 DrBarken
Dr. Slovin Discusses a Study Comparing Cardiovascular Events With Degarelix or Leuprolide
 
02:42
Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses a multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with prostate cancer and cardiovascular disease receiving degarelix, a GnRH receptor antagonist, or leuprolide, a GnRH receptor agonist.
Views: 127 OncLiveTV
Dr. Mary-Ellen Taplin on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
 
01:41
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, discusses a randomized phase II trial that provided abiraterone acetate (Zytiga) in combination with the hormonal therapy leuprolide acetate before prostatectomy for men with localized high-risk prostate cancer (LHRPC).
Views: 632 OncLiveTV
Link Discovered Between Hormone Therapy for Prostate Cancer and Depression
 
00:51
A new study suggests older men who receive testosterone-suppressing therapy for prostate cancer may be at increased risk of developing depression. The findings are based on a large study of 78,000 U.S. men treated for earlier-stage prostate cancer. Researchers found that among those given hormone-suppressing therapy, 7 percent developed clinical depression in the next few years. 5 percent of men who did not have the treatment also developed depression. The findings do not prove that hormone therapy is to blame. However, senior researcher Dr. Paul Nguyen of Brigham and Women's Hospital in Boston says they do offer "pretty strong evidence" that might be the case. Nguyen said his team accounted for some other factors that could affect depression risk -- including the severity of a man's cancer, his age and education. And there was still a connection between hormone therapy and depression. Also, the longer the men were on hormone therapy, the higher the risk of depression. http://www.upi.com/Health_News/2016/04/11/Hormone-therapy-for-prostate-cancer-tied-to-depression/9031460418049/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Views: 278 Wochit News
Urologist says female hormone injections pose risks for those with prostate cancer
 
02:06
Every year, 50,000 American men have a recurrence of prostate cancer because their first treatment failed.
Views: 316 WPLG Local 10
Benign Prostate Hyperplasia (BPH) and Prostate Cancer for USMLE Step 2
 
34:35
Benign Prostatic Hyperplasia (BPH) and Prostate Cancer epidemiology, etiliogy, causes and symptoms, investigations, treatment and management. Handwritten full lecture for USMLE. ANATOMY of PROSTATE Central zone of prostate sorrounds ejaculatory duct. The Transitional zone of prostate encompases meddle part of urethra. Peripheral zone is placed outside. Prostate cancer is most common in peripheral zone (60-70%). The Central zone is the second most common site for prostate cancer (25%). The Transition zone only has an occurence rate of 5% for prostate cancer. Benign Prostate Hyperplasia (BPH) is in the transition zone and that is why it presents mostly with urinary symptoms. BENIGN PROSTATIC HYPERPLASIA (BPH) Prostate is heavily influenced by DHT and testosterone, however, DHT is ten times more sensitive. Testosterone is converted to DHT by 5alpha reductase. This causes hyperplasia of collagen cells and the smooth muscle. The collagen will cause a physical obstruction while the smooth muscle will cause mechanical obstruction. Eventually there is bladder enlargement which may forma false diverticulum (outpouching of the bladder). Clinical Signs and Symptoms Obstructive symptoms - Consists of the patients experiencing hesitancy, difficulty voiding, straining, decrease in the force of stream and dribbling of urine. Irritation symptoms - increase frequency or urgency as well as nocturia. These symptoms occur as the bladder gets larger and begins to overflow. These symptoms can produce an International Prostate Symptoms Score (IPSS) which determines severity of Benign prostatic Hyperplasia through symptoms. Diagnosis of Benign Prostatic Hyperplasia Digital Rectum Exam is done initially, however it doesn't correlate well with symptoms and it is very difficult to palpate. Urinalysis is also done to rule out prostatitis. PSA is organ specific but can be elevated in cancer and prostatitis. Ultrasound or CT to look for complications such as bladder distention. Transrectal ultrasound is used before surgery. Treatment for Benign Prostatic Hyperplasia (BPH) If the degree of benign prostatic hyperplasia (BPH) is minimal such as 0-7 on the IPSS score than watchful waiting because most spontaneously. So for these patients continue monitoring PSA and Digital Rectums Exams. If getting worse continue to medical treatment. Alpha 1 blocker allows relaxation of the smooth muscle that may be constricting the urethra. Finasteride is a 5 alpha reductase inhibitor to prevent formation of DHT from testosterone and help debulk the prostate. Commonly used drugs are terazosin and doxazosin but this can lead to hypotension. More specific is an Alpha A1 blocker such as tamsolusin which is more specific for the prostate and therefore hypotension is not present but can lead to retrograde ejaculation. Surgery - If medical therapy doesn't work for the Benign Prostatic Hyperplasia (BPH). Two procedures transurethral and prostatectomy. PROSTATE CANCER CLINICAL SIGNS AND SYMPTOMS of PROSTATE CANCER Can range from asymptomatic to completely fatal. Screening - Digital Rectal Exam is not helpful and PSA is the only method being used. Local Disease causes symptoms similar to Benign Prostatic Hyperplasia symptoms, but this suggests involvement of the transition zone. Metastasis disease include symtpoms related to osteoblastic bone growth, primarily the spine leading to neurological symptoms and back pain. Prostatic Cancer patients may also have patients related to lower extremities due to lymphatic obstruction INVESTIGATION for PROSTATE CANCER Digital Rectal Exam shows a single nodule and correlates well with severity of disease. However, it may be a cyst or a stone. PSA normally should be less than 2.5ng/dL (some say less than 4 ng/dL). May also be helpful to measure as PSA Velocity and Free PSA versus Bound PSA. This helps distinguish Benign Prostatic Hyperplasia from Prostate Cancer. Transrectal Ultrasound may also be used. Biopsy uses the Gleasson Score which looks at the tissue of prostate under microscope and given a score out of 5. Staging of prostate cancer utilizes the TNM score. TREATMENT AND MANAGEMENT of PROSTATE CANCER Start with active surveillance by monitoring PSA/DRE/Biopsies. Radiation - Has a lot of GIT complications and may lead to erectile Dysfunction. Brachytherapy is the new treatment. Radical Prostatectomy - May lead to neruovascular damage causing Erectile Dysfunction and damage to urethra my lead to incontinence. After treatment continue to monitor PSA to look for Metastasis or resurgency of cancer. TREATMENT OF METASTASIS OF PROSTATE CANCER Castration - Orchiectomy (Gold Standard), Leuprolide/Ghrelin (GnRH) but these have a temporary increase in androgens, and Anti-Androgens (Flutamide). Castration Resistant Prostate Cancer (CRPC) are tumors that are still growing despite castration. Then use chemotherapy (Doxitexal, Mitoxantrone, Dosatinib)
Views: 33812 the study spot
Hormonal Therapy for Prostate Cancer
 
22:00
A discussion of hormonal therapy for prostate cancer patients considering their treatment options
Views: 27116 CancerClinicalTrials
Lupron Depot Side Effects - Physical Symptoms (and House Hunt)
 
14:22
An update on my symptoms post Lupron Depot injection and other things. Insta: instagram.com/liv4todayvlog Facebook: https://www.facebook.com/liv4todayvlog/ blog: femmeinfertile.blogspot.com Music: http://www.bensound.com/royalty-free-music
Views: 3494 Liv 4 Today
Lupron meds giggles 2009
 
02:05
I thought this video was lost. Giggles from the cancer medication I was taking back then. what a great side effect
Views: 140 Rick Luepke
Dr. Moul Discusses the Long-Term Tolerability and Efficacy of Degarelix
 
01:50
Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.
Views: 169 OncLiveTV
Day 1 on Lupron Depot.
 
01:06
Just doing a video blog on lupron. Treatment for endometriosis. This medication is testosterone.
Views: 1169 Megan
Is Abiraterone Acetate Useful for Prostate Cancer?
 
02:30
Some reports suggest that Abiraterone Acetate may be a new treatment for prostate cancer. Find out the latest information.
Views: 2897 Gerald Chodak MD
ZERO Prostate Cancer Run Walk - Capital Area PSA
 
01:10
The 2018 ZERO Prostate Cancer Run/Walk - Capital Area takes place on Saturday, June 16, 2018 at 8:15 a.m. at Pentagon Row Courtyard. It features a 5K run/walk, 1 mile walk, Kids' Superhero Dash for Dad, and virtual Snooze for Dudes program. Stick around for the family-friendly post-race celebration. Participants will receive shirts, free food, and the opportunity to connect with others who are impacted by prostate cancer.
The Role of Abiraterone in Prostate Cancer
 
02:06
Charles J. Ryan, MD, professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, discusses the role of abiraterone acetate (Zytiga) in the treatment of patients with prostate cancer, and the questions that remain about its use.
Views: 681 Targeted Oncology
LUPRON DAY 4.My Thoughts on Leuprolide so far
 
01:24
Thanks For Watching !!!
Views: 166 Nickeyibelieve30
Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials
 
01:32
Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.
Views: 66 OncLiveTV
Biotech Sector Update FDA Prostate Cancer Drug to Include Warning Update
 
01:54
http://www.StockMarketFunding.com FDA confirms that it asked drug manufacturers to include warnings on risk for class of prostate cancer drugs. The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer. The warnings would alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications. GnRH agnoists are marketed under the brand names: Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex. Several generic products are available. (SGEN, MIPI, RNN, OGXI, DNDN, ISIS, ISR, MYGN, MDVN, PFE, AZN)
The Health Of My Ovaries And Uterus // Lupron Side Effects
 
04:28
I went in for a Saline Sonohysterogram to have my ovaries and uterus checked out. I have done this before but its been quite a few years so time for another checkup! Also, I talk about some of the side effects that I have been having with the Lupron. Thanks for watching! www.bensound.com
Views: 616 Abby and Mike
Lupron Cost
 
00:31
To buy Lupron at the lowest price-guaranteed!-visit http://www.luproncost.com
Views: 388 hopecollins13
New Therapies for Castration Resistant Prostate Cancer.mp4
 
04:29
New Therapies for Castration Resistant Prostate Cancer.mp4
Views: 204 DrBarken
First Lupron Injection
 
03:34
Watch me give myself my first Lupron (leuprolide acetate) injection. Wasn't as bad as I thought. =) Excuse me...I kept looking at myself instead of the camera. Injection #1 DONE!
Views: 10455 MrsKayJay
Prostap Injection
 
02:47
Can i first say sorry for the camera being the wrong way. Well her goes everyone, it has finally begun. I want to just show you how to administer the prostap correctly. Hope it helps. xxxxxx
Views: 42151 Kerry Wiles
Dr. Wise on the Development of Precision Medicine in Prostate Cancer
 
01:19
David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.
Views: 94 OncLiveTV
Oncology, prostate cancer diagnostics and treatment
 
02:53
Benefits of Latvian medical and health products are: high product and service quality, professional medical staff, latest medical equipment to ensure services, without long queues and at competitive prices. In addition, cluster partners are able to provide English speaking medical staff, so there is no language barrier, and free communication on health issues gives patient a sense of security, trust and confidence that a proper choice has been made to receive high-quality services from the professional medical staff of Latvia. http://www.healthtravellatvia.lv/en Latvian Health Tourism Cluster was established in 2012 with an aim to provide high quality medical services to foreign patients as well as locals. There are 60 cluster members, wide variety of health tourism providers: government, municipality and regional hospitals, private clinics, rehabilitation centers, resort hotels, travel agencies, educational and research institutions.
Let's Talk about Prostate Cancer with Alan J. Katz, MD
 
06:59
Dr. Katz is a radiation oncologist who has now treated over 600 prostate cancer patients with the CyberKnife stereotactic body radiation system. In this video he discusses his experience with the use of this method for the treatment of localized prostate cancer.
Views: 1377 PCaInternational
Dr. Mary-Ellen Taplin on Dual Pathway Inhibition in Prostate Cancer
 
03:10
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, discusses clinical trials that are investigating preclinical evidence that the dual blockade of the androgen receptor and the PI3K/AKT/mTOR pathway is an effective approach in prostate cancer. For more information on hormone inhibitors, visit http://targetedtherapies.onclive.com/targeted/hormones
Views: 556 Targeted Oncology
Dr. Mary-Ellen Taplin on Neoadjuvant ADT Plus Hormonal Therapy for Prostate Cancer
 
01:49
Mary-Ellen Taplin, MD, associate professor of Medicine at Harvard Medical School and the Dana-Farber Cancer Institute, explains the rationale behind the recent study examining the neoadjuvant administration of abiraterone acetate (Zytiga) in combination with the LHRH analog leuprolide acetate, for patients with localized high-risk prostate cancer. To read more, visit http://www.onclive.com/onclive-tv/Dr-Taplin-on-Neoadjuvant-ADT-Plus-Hormonal-Therapy
Views: 292 OncLiveTV
NICE decision to reject prostate cancer drug Abiraterone
 
02:46
Prostate Action CEO Emma Malcolm discusses the decision from NICE to reject Abiraterone for use by the NHS, a drug used to treat advanced prostate cancer.
Views: 594 ProstateAction